Streptococcal C5a peptidase vaccine
AssigneeRegents of the University of Minnesota
InventorsPaul Patrick Cleary, Deborah K. Stafslien
Life of this patent
Estimating the term…
Abstract
Novel vaccines for use against β-hemolytic Streptococcus colonization or infection are disclosed. The vaccines contain an immunogenic amount of a variant of streptococcal C5a peptidase (SCP). Also disclosed is a method of protecting a susceptible mammal against β-hemolytic Streptococcus colonization or infection by administering such a vaccine. Enzymatically inactive SCP, and polynucleotides encoding these SCP proteins are further disclosed.
Claims10
A composition comprising an isolated enzymatically inactive streptococcal C5a peptidase (SCP) conjugated or linked to a polysaccharide, wherein the SCP comprises the specificity crevice or catalytic domain of SCP.
Dependencies are inferred from the claim text.